Identification of Potential Predictors of Prognosis and Sorafenib-Associated Survival Benefits in Patients with Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization

Some studies have shown that sorafenib could significantly prolong the overall survival of patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization (TACE). However, other studies revealed that patients had no access to sorafenib-related survival benef...

詳細記述

書誌詳細

出版年:	Current Oncology
主要な著者:	Kun He, Zelong Yang, Xinyu Liu, Yanling Yang, Wenjie Song, Shangyu Wang, Yong Chen
フォーマット:	論文
言語:	英語
出版事項:	MDPI AG 2022-12-01
主題:	predictors hepatocellular carcinoma vascular endothelial growth factor transcatheter arterial chemoembolization sorafenib
オンライン･アクセス:	https://www.mdpi.com/1718-7729/30/1/38